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epression is considered to be an independent
risk factor for cardiovascular mortality and morbidity in
patients with ischemic heart disease (IHD).
1,2The risk of
cardiovascular disease is higher in individuals suffering
from depression,
3 as is the risk of ischemic stroke.
4
Among newly diagnosed patients with coronary heart
disease,approximately one in five patients suffers from
major depression,with a similar prevalence in patients
recovering from acute myocardial infarction.
5,6The pro-
posed mechanisms are either spurious,ie,that depression
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Antidepressants, particularly selective serotonin reuptake inhibitors (SSRIs), are widely used for the treatment of depres-
sion and anxious disorders. The observation that depression is an independent risk factor for cardiovascular mortality and
morbidity in patients with ischemic heart disease, the assessment of the central role of serotonin in pathophysiological
mechanisms of depression, and reports of cases of abnormal bleeding associated with antidepressant therapy have led
to investigations of the influence of antidepressants on hemostasis markers. In this review, we summarize data regard-
ing modifications of these markers, drawn from clinical studies and case reports. We observed an association between
the type of antidepressant drug and the number of abnormal bleeding case reports, with or without modifications of
hemostasis markers. Drugs with the highest degree of serotonin reuptake inhibition—fluoxetine, paroxetine, and ser-
traline—are more frequently associated with abnormal bleeding and modifications of hemostasis markers. The most fre-
quent hemostatic abnormalities are decreased platelet aggregability and activity, and prolongation of bleeding time.
Patients with a history of coagulation disorders, especially suspected or documented thrombocytopenia or platelet dis-
order, should be monitored in case of prescription of any serotonin reuptake inhibitor (SRI). Platelet dysfunction, coag-
ulation disorder, and von Willebrand disease should be sought in any case of abnormal bleeding occurring during treat-
ment with an SRI. Also, a non-SSRI antidepressant should be favored over an SSRI or an SRI in such a context. Considering
the difficulty in performing platelet aggregation tests, which are the most sensitive in SRI-associated bleeding, and the
low sensitivity of hemostasis tests when performed in case of uncomplicated bleeding in the general population, estab-
lishing guidelines for the assessment of SRI-associated bleeding complications remains a challenge.   
© 2007, LLS SAS Dialogues Clin Neurosci. 2007;9:47-59.predicts, but is not causally related to, cardiovascular
heart disease morbidity and mortality (antidepressant
cardiotoxicity,association with cardiac risk factors,seden-
tary lifestyle),or imply that depression may directly influ-
ence the course of cardiac heart disease (nonadherence
to cardiac treatment and regimens,dysregulation of auto-
nomic,neuroendocrine,and serotonergic systems).
7
Serotonergic neurotransmission dysfunction has been
investigated and observed in major depression.
8,9Various
findings support the hypothesis that alterations in sero-
tonergic neurons play a role in the pathophysiology of
depression,
10 and most antidepressants have a direct
influence on serotonin (5-HT) transmission and levels.
5-HT is usually a vasodilator,becoming a vasoconstric-
tor when the endothelium is damaged.
11 It is also
involved in platelet aggregation. It is taken up from
plasma and stored in platelet granules.Upon initiation of
platelet aggregation,5-HT is released into the blood and
activates 5-HT2A receptors on the platelet membrane,
which enhances the aggregation process.5-HT per se is
a weak activator,but dose-dependently enhances platelet
activation induced by adenosine diphosphate (ADP)
and, in particular, thrombin in whole blood.
12 It also
potentiates aggregation in the presence of epinephrine
or collagen,
13 and potentiates release reactions through a
mechanism of amplification by an increase in free cyto-
plasmic intracellular calcium ion concentration. This
induces a shape-change reaction of platelets, priming
platelet surfaces for interactions with coagulation fac-
tors.
14 5-HT may therefore be directly involved in
increased cardiovascular mortality and morbidity in
depressed patients.
A relationship between depressive symptoms and
increased platelet activity has been established in physi-
cally healthy depressed patients
15-17 as well as in post-
myocardial infarction (MI) depressed patients.
8,18The fol-
lowing mechanisms mediating platelet abnormalities
observed in major depression have been proposed
19:
altered platelet function by increased plasma concentra-
tions of 5-HT and epinephrine,affected platelet function
by increased intraplatelet calcium mobilization,upregula-
tion of 5-HT2A receptors or α-adrenoreceptors,downreg-
ulation of 5-HT transporter number,altered second mes-
senger signal transduction, or altered intraplatelet
concentrations of monoamines and catecholamines.
17
Thus,5-HT probably plays a role in the pathophysiolog-
ical mechanisms of depression as well as in primary
hemostasis platelet activity, and this neurotransmitter
might be a key element in the understanding of the rela-
tionship between depression and increased risk of car-
diovascular disease.Amplification of platelet aggregation
could be altered by antidepressants that inhibit serotonin
reuptake,in particular selective 5-HT reuptake inhibitors
(SSRIs),because of depletion or decrease in intraplatelet
5-HT levels.The purpose of this review of the literature
is to summarize changes in hemostatic function observed
during treatment by antidepressants.
We performed a MEDLINE search of the relevant liter-
ature,and reviewed prospective and retrospective stud-
ies, as well as case reports and reviews of literature
related to bleeding side effects and hemostasis labora-
tory findings,associated with antidepressant treatment in
the psychiatric population,in post-MI depressed patients,
or in healthy volunteers.
The prothrombotic effect of typical and atypical antipsy-
chotics, as well as the impaired platelet function and
thrombocytopenia caused by the mood stabilizer val-
proate and the possible procoagulant effect of treatment
by lithium,are not examined here.
Hemostasis
The process of hemostasis involves four principal stages:
first,the initiation and formation of the platelet plug (also
called primary hemostasis),second,the coagulation cas-
cade,a series of enzymatic actions on proteins leading to
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Selected abbreviations and acronyms
5-HT  5-hydroxytryptamine (serotonin)
AA  arachidonic acid
ADP  adenosine diphosphate
aPTT  partial thromboplastin time
TG  -thromboglobulin
IHD  ischemic heart disease
INR international normalized ratio
MI  myocardial infarction
NSAID  nonsteroidal anti-inflammatory drug
PDGF  platelet-derived growth factor
PF4  platelet factor 4
PFA  platelet function analyzer
PIT  platelet inositol triphosphate
PT  prothrombin time (Quick)
SRI  serotonin reuptake inhibitor
SSRI  selective serotonin reuptake inhibitor
TT  thrombin time
TXA2 thromboxane A2
vWF  von Willebrand factorclot formation;third,its termination by antithrombotic
control mechanisms;and fourth,the removal of the clot
by fibrinolysis.The coagulation cascade leads to forma-
tion of fibrin polymers which consolidate the platelet
plug formed during primary hemostasis.
20Abnormalities
in tests measuring the function of primary hemostasis
and clotting cascade (coagulation) have been reported in
case reports and cohort studies in patients treated with
antidepressants.
During primary hemostasis,the platelets form a plug at
a site of injury in order to stop bleeding. This phase,
which is the functional response of activated platelets,
comprises four different processes: adhesion, aggrega-
tion, secretion, and procoagulant activity.
21 During the
vascular phase,vasoconstriction occurs and procoagulant
(von Willebrand factor [vWF], tissue factor) as well as
anticoagulant substances prostaglandin I2 [PGI2],throm-
bomodulin,urokinase,tissue plasminogen activator [t-
PA],antithrombin,nitric oxide [NO],and endothelium-
derived relaxing factor [EDRF]) are secreted by the
endothelium.The most potent platelet activators are col-
lagen and thrombin,whereas ADP and epinephrine are
weak activators.5-HT itself is a weak platelet agonist,but
it amplifies the effect of other platelet agonists.
22 The
process comprises successive steps,illustrating the cen-
tral role of platelets (Figure 1):
•Adhesion:Platelets change shape in response to acti-
vation,allowing adhesion to subendothelial matrix.This
process is mediated by the binding of platelet surface
receptor GPIb/IX/V complex to vWF.Binding of col-
lagen to platelet collagen receptor GPIa/IIa also plays
a role in platelet adhesion.
•Aggregation: Both conformational and exposure
changes in the GPIIb/IIIa on the platelet surface due
to activation,result in binding of vWF and fibrinogen.
• Secretion:Substances are secreted from platelet granules
upon stimulation.ADP and 5-HT stimulate and recruit
other platelets.Fibronectin stabilizes platelet aggregates.
Secreted fibrinogen provides a source of fibrinogen at
sites of endothelial injury in that present in the plasma.
Thromboxane A2 (TXA2,from arachidonic acid [AA]
release) stimulates platelet aggregation and causes vaso-
constriction. Platelet-derived growth factor (PDGF)
mediates tissue reparation.
• Procoagulant activity:Exposure of procoagulant phos-
pholipids and the subsequent assembly of the enzyme
complexes on the platelet surface represent procoagu-
lant activity.
Among others,the following laboratory tests explore pri-
mary hemostasis:platelet count,bleeding time,platelet
function analyzer (PFA),platelet functional assessment,
medullogram,and vWF.(Table I).Normal values are not
mentioned, since they are provided by the laboratory
when these examinations are requested.
The clotting cascade consists of the activation of various
proenzymes to active enzymes,resulting in the formation
of the red clot.Intrinsic and extrinsic pathways lead to
activation of factor X which converts prothrombin to
thrombin,the final enzyme of the clotting cascade,which
in turns converts fibrinogen into an insoluble fibrin clot.
Among others, the following laboratory tests examine
the clotting cascade:prothrombin time (PT) and inter-
national normalized ratio (INR,extrinsic pathway),par-
tial thromboplastin time (aPTT,intrinsic pathway),fib-
rinogen, thrombin time (TT), coagulation factors, and
inhibitors of coagulation (antithrombin,proteins C and
S, Table I).
Influence of antidepressants on 
hemostasis markers
Numerous prospective open comparative studies,
9,16,23-34
randomized double-blind controlled trials,
8,35-37 in vitro
studies by incubation of the antidepressant compound,
38-40
and case reports
41-53 have pointed out changes in labora-
tory tests assessing function of primary hemostasis and
clotting cascade.
Double-blind, randomized, placebo-controlled trials
In a randomized,double-blind,placebo-controlled,two-
way crossover trial,Hergovich et al evaluated the poten-
tial inhibition of platelet function in 16 healthy male vol-
unteers receiving paroxetine, 20 mg/d over 2 weeks.
Paroxetine decreased intraplatelet 5-HT concentration
by 83% and therefore prolonged closure time measured
by PFA by 31% (in other terms inhibited the plug under
shear stress). It also lowered platelet activation in
response to thrombin receptor peptide,shown by an 8%
decrease in the expression of the platelet activation
marker CD63. No changes in plasma concentration of
prothrombin fragment, vWF antigen, or soluble P-
selectin were observed.This indicated no activation of
coagulation,endothelium,or platelet in vivo,underlining
a favorable risk:benefit ratio when the drug is used for
rehabilitation of post-MI patients.
35
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Figure 1. Diagrammatic representation of primary hemostasis. 5-HT, serotonin; vWF, von Willebrand factor; ADP, adenosine diphosphate; βTG, 
β-thromboglobulin; PF4, platelet factor 4; MLC, myosine light chain; MLCK, myosine light chain kinase; PGG2, prostaglandin G2; PGH2,
prostaglandin H2; PIP2, phosphatidylinositol 3,4-bisphosphate; PKC, protein kinase C; P47, pleckstrin phosphoprotein; TK, tyrosine kinase;
PECAM, platelet endothelial cell adhesion molecule; DAG, diacylglycerol; COX, cyclo-oxygenase
Adapted from ref 21: Colman RW, Clowes AW, George JN, et al. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. Fifth ed. Philadelphia,
Pa: Lippincott Williams and Wilkins; 2006. Copyright © Lippincott, Williams and Wilkins 2006.
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GP IbIn order to investigate whether depressed post-MI
patients have higher markers of platelet activation than
nondepressed post-MI patients,and evaluate the effect
of mirtazapine on platelet activation, Schins et al con-
ducted a randomized,double-blind,placebo-controlled
trial in 25 depressed post-MI patients receiving, for 8
weeks, either mirtazapine 30 to 45 mg or placebo.The
control group consisted of nondepressed post-MI
patients.The markers measured were plasma levels of β-
thromboglobulin (βTG),platelet factor 4 (PF4),soluble
CD40 ligand (sCD40L),whole-blood,and intraplatelet
5-HT. Before treatment, only whole blood and
intraplatelet 5-HT levels were significantly higher in
depressed patients.Treatment with mirtazapine resulted
in a nonsignificant decrease in βTG, PF4, and
intraplatelet 5-HT level after 8 weeks.The authors under-
line the fact that mirtazapine,by lack of inhibitory effect
on 5-HT reuptake,has not shown,in contrast with SSRIs,
a potentiated risk of bleeding events,when given in com-
bination with nonsteroidal anti-inflammatory drugs
(NSAIDs).
54-56Therefore,treatment of depressed post-MI
patients with mirtazapine may be possible in patients sus-
ceptible to bleeding complications, according to the
authors.
8
In a randomized,double-blind,placebo-controlled trial,
Serebruany et al assessed the release of platelet/endothe-
lial markers in 64 post-MI depressed patients treated
with sertraline vs placebo.PF4,βTG,platelet/endothelial
cell adhesion molecule-1, P-selectin, thromboxane B2
(TXB2),6-ketoprostaglandin F1α,vascular cell adhesion
molecule-1,and E-selectin were measured by enzyme-
linked immunosorbent assay (ELISA).Treatment with
sertraline was associated with substantially less release
of these markers than treatment with placebo.These dif-
ferences reached statistical significance for βTG at weeks
6 and 16 and for P-selectin at week 16.Repeated-mea-
sures ANOVA revealed a significant advantage for ser-
traline vs placebo for diminishing E-selectin and βTG
concentrations across the entire treatment period.
Despite previous broad use of aspirin and clopidogrel
(though equally distributed between both groups),the
authors underline the potential benefit of sertraline treat-
ment of post-MI patients,because of decreased activa-
tion of platelets.
36
Double-blind, randomized, comparative trial
Pollock et al investigated the influence of a 6-week
paroxetine or nortriptyline treatment on platelet activa-
tion in 17 depressed patients with IHD,in a randomized
double-blind trial.Baseline measurements of βTG and
PF4 were significantly elevated in both groups before
treatment,compared with those of healthy control sub-
jects.In the paroxetine group,mean βTG and PF4 levels
significantly decreased within 1 week of treatment and
remained low at the 3- and 6-week measurements. In
contrast,the nortriptyline group did not exhibit a signif-
icant decrease in βTG and PF4 levels after 1, 3, and 6
weeks.A type II error for the nortriptyline group was not
excluded;nor was the possible influence of the patient's
clinical state on platelet activation.However,according
to the authors, the reduction in platelet activation
observed after only 1 week of paroxetine treatment is in
favor of a pharmacologic effect.
37
Prospective open comparative studies
Prospective open comparative studies, conducted in
depressed patients,post-MI depressed patients,or healthy
volunteers, with comparative measurements of various
hemostasis parameters in a healthy control group or in
subjects before treatment,demonstrated higher platelet
activity in depressed or post-MI depressed patients in
comparison with the control group, and/or decrease in
platelet activity after antidepressant treatment.
Alvarez et al showed that untreated depressed patients
have decreased numbers of platelet 5-HT transporter
sites and increased levels of platelet inositol triphosphate
(PIT), that treatment with both fluoxetine and
clomipramine further reduces the density of these trans-
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Table I. Laboratory tests of hemostasis. This list does not concern the third
and fourth stages of hemostasis; the process is terminated by
antithrombotic control mechanisms and fibrinolysis.
Primary hemostasis Coagulation cascade
Platelet count Prothrombin time (extrinsic 
pathway)
Bleeding time Partial thromboplastin time 
(intrinsic pathway)
Platelet function analyzer Fibrinogen
Platelet functional assessment  Thrombin time
(Platelet aggregation)
von Willebrand Factor  Coagulation factors
Inhibitors of coagulation 
(antithrombin, proteins C 
and S)porter sites (more marked in responders to treatment),
accompanied by a dramatic decrease in plasma and
platelet 5-HT levels,and that,in responders,PIT levels
return to normal values.
9
Markovitz et al showed a greater platelet secretory
response to collagen in depressed patients than in healthy
control subjects in baseline comparison measures.They
then demonstrated a decrease in collagen-induced platelet
secretion after treatment with sertraline for 6 weeks,most
other platelet activation measures showing minimal
change. These changes were, however, not related to
improvement in the Beck Depression Inventory scores,
but this finding might be limited by the short treatment
duration.Thus,the decreased platelet activation after SSRI
treatment could diminish the risk of coronary heart dis-
ease among depressed subjects,but the authors underline
the need for studies in a large number of patients,placebo
controls,and a longer follow-up period.
24
In a study by Musselman et al,after 6 weeks of open-label
treatment with paroxetine,a normalization of platelet acti-
vation occurred in patients with depression. This was
shown by a significant decrease in PF4 and of the platelet
monoclonal antibodies anti ligand-induced platelet bind-
ing site (LIBS) and GA6 (anti P-selectin).Before treat-
ment, these markers were higher among depressed
patients compared with the control group.The results of
this study could be explained by recovery from depression.
Thus,studies with placebo and/or psychotherapy are pro-
posed by the authors as further investigation.
25
A decrease in platelet response mediated by the 5-HT2A
receptor following effective imipramine treatment was
demonstrated by Gomez-Gil et al,shown by a significant
decrease in 5-HT-amplified platelet aggregation to ADP,
thus suggesting that desensitization or downregulation of
platelet 5-HT2A receptor function could be linked to a
therapeutic effect of some antidepressants.
30
Comparing levels of plasma 5-HT and platelet 5-HT
induced aggregation among depressed patients treated
with either fluoxetine or amitriptyline and nontreated
patients,Menys et al demonstrated a statistically signifi-
cant decrease in both plasma 5-HT levels and 5-HT
induced platelet aggregation,only with fluoxetine.This
suggests a higher inhibition of platelet activity by SSRIs
than tricyclic antidepressants,and therefore a more suit-
able treatment for depressed patients with cardiovascu-
lar disease.
26
Laine-Cessac et al failed to demonstrate a significant
effect of a 1-month fluoxetine treatment in 8 depressed
patients,on the following primary hemostasis and coag-
ulation tests: PT, aPTT,TT, fibrinogen, platelet count,
bleeding time,platelet aggregation induced by ADP,AA,
ristocetin,and collagen.The single statistically significant
difference,in comparison with values before treatment,
was found in a decreased velocity in platelet aggregation
induced by epinephrine.The authors conclude that sig-
nificant platelet dysfunction causing hemorrhagic diathe-
sis is uncommon when fluoxetine is used at a dosage of
20 mg daily.
27 However,methodological issues with this
publication suggest a high risk of type II error.
27
Lederbogen et al measured aPTT,vWF,fibrinogen,fib-
rin monomer,and prothrombin ratio (Quick) before and
after treatment with either amitriptyline or paroxetine.
Therapy was effective on depressive symptoms as mea-
sured by the Hamilton Depression scale in both groups,
and ANOVA revealed prothrombin ratio to increase
from start to end of treatment.No effect was seen on the
other parameters. The authors conclude that changes
observed in prothrombin ratio may be due to nutritional
factors,and that bleeding associated with antidepressant
therapy is probably not an extreme form of a general
influence on the coagulation systems,but rather an idio-
syncratic reaction.
32
Berk et al studied 10 patients before and after treatment
with fluoxetine. No changes in any index of platelet
aggregation or coagulation were reported.
33Alderman et
al were also unable to demonstrate any changes in pri-
mary hemostasis or coagulation parameters after use of
fluoxetine or paroxetine for 28 days.
28This was also the
case after a fluoxetine trial conducted by Bang et al.
34
Interestingly,Tharmapathy et al observed that platelets
from six or seven patients undergoing treatment with ven-
lafaxine aggregated spontaneously during a routine cen-
trifugation of platelet-rich plasma.Furthermore,increased
baseline platelet activity as measured by P-selectin surface
expression was observed during treatment compared with
before treatment.
29
In vitro studies
The in vitro effects of escalating concentrations of ser-
traline on human platelets were assessed by Serebruany
et al, showing a dose-dependent inhibition of platelet
aggregation induced by ADP,collagen,and thrombin,as
well as decreased platelet surface expression of CD9,P-
selectin, platelet endothelial cell adhesion molecule
(PECAM)-I,and glycoproteins IIb/IIIa and Ib.The data
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platelets of therapeutic concentrations of sertraline,sug-
gest that it may account for a substantial portion of the
association between depression and adverse outcomes of
IHD by a thrombotic mechanism.
39
Mohammad and Mason also demonstrated an inhibition
of ADP-induced platelet aggregation by the tricyclics
imipramine and amitriptyline.
38
Case reports (no baseline values)
Among case reports of abnormal bleeding with antide-
pressant medication,some have revealed abnormalities
in hemostasis tests.Alderman et al and De Maistre et al
reported cases of abnormal bleeding associated with flu-
oxetine treatment,accompanied by a decrease in ADP,
epinephrine,ristocetin,AA,collagen,and epinephrine-
induced platelet aggregation, respectively, which were
reversible after discontinuation of the drug (positive
dechallenge).
41,42
Ottervanger et al reported a decrease in epinephrine-
induced platelet aggregation in a patient treated with
paroxetine for 4 weeks.
45
A decrease in ADP and ristocetin-induced platelet aggre-
gation in a patient treated with fluoxetine was also
reported by Evans et al.They also described an increase
in bleeding time to more than 25 minutes,with positive
dechallenge and rechallenge.
46
Increased bleeding time with positive dechallenge was
reported by Humphries et al in a patient treated for 2
years with fluoxetine,and by Calhoun and Calhoun for a
patient treated for 10 weeks with sertraline.
47,48
Ceylan and Alpsan-Omay also described the case of a
patient treated with sertraline for 7 days,with prolonged
bleeding time and prothrombin time, as well as a
decrease in platelet count.All three parameters reversed
after discontinuation (positive dechallenge).
49
Low platelet count was also noted by Aranth and
Lindberg and Leung and Shore in patients treated
respectively with fluoxetine and fluvoxamine.
43,44
Tham et al,Demet et al,and Tielens reported prolonged
aPTT with venlafaxine, mirtazapine, and paroxetine
respectively.
50,51,53 In the first two cases,values returned to
normal range after discontinuation (positive dechal-
lenge).Tham et al also reported a high antihemophilic
factor VIII, whereas Demet et al showed a prolonged
prothrombin time and increased INR.
50,51
In contradiction with these findings,a case of diminished
prothrombin time and aPTT was reported by Hardy and
Sirois when trazodone was added to treatment with war-
farin after mitral valve replacement,thus decreasing the
efficiency of this treatment.
52
Table II summarizes the discussed clinical studies on
modification of hemostasis markers, while Table III sum-
marizes the case reports.
Discussion
In this review, we have presented the modifications of
hemostasis markers caused by antidepressants.The most
frequent modifications are decreased platelet aggregabil-
ity and activity, and prolongation of bleeding time (pri-
mary hemostasis);they are more likely to occur with anti-
depressants such as fluoxetine,sertraline,or paroxetine.
Other antidepressants such as venlafaxine,fluvoxamine,
amitriptyline,imipramine,and even mirtazapine,can also
influence hemostasis.Modifications of platelet count,as
well as PT and PTT (coagulation cascade) are much less
frequent.It is not known whether there might be labora-
tory modifications in the last two stages of hemostasis,ie,
the termination by antithrombotic control mechanisms
and the removal of the clot by fibrinolysis.
Antidepressants that inhibit platelet reuptake of 5-HT
cause a platelet 5-HT depletion.This can inhibit 5-HT-
induced platelet aggregation amplification.Patients suf-
fering from bleeding complications during antidepressant
treatment may have a mild pre-existing platelet disorder
or a modified platelet serotonergic response amplified by
depletion of 5-HT stocks
57;autoimmune mechanisms may
also be involved.
50
Different types of studies were performed, from case
reports to epidemiological studies and prospective labo-
ratory studies comparing subjects and controls receiving
antidepressants.These studies did not lead to the same
conclusions.
A causal association between use of antidepressants,espe-
cially SSRIs,and abnormal bleeding or need for transfu-
sion during surgical procedures has been found in retro-
spective studies.
54-56,58-61The main observation concerns a
relationship between the type of antidepressant drug and
the risk of bleeding complications.The risk of upper gas-
trointestinal bleeding was twice as high for SSRIs than for
other antidepressant drugs.
55The risk of upper gastroin-
testinal bleeding in elderly and depressed patients
increased with antidepressants having the greatest extent
of inhibition of 5-HT reuptake.
56 Similarly, a significant
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Type of study Subjects N° Treatment SS modifications of hemostasis markers
Pollock et al, 2000
37 Randomized, DB DEP + IHD 17 Paroxetine or  Paroxetine: ↓β TG (P<0.01), PF4 (P<0.001);
nortriptyline (6 weeks) Nortriptyline: non-SS: ↓ PF4
Serebruany et al, 2003
36 Randomized, Post-MI DEP 28 Sertraline (16 weeks) ↓β TG (P=0.03), P-selectin (P=0.04), 
DB, PC E-selectin and βTG (ANOVA); 
non-SS: ↓ PF4, PECAM-I
Schins et al, 2004
8 Randomized,  Post-MI DEP 25/21 Mirtazapine (8 weeks) Non-SS: ↓β TG, PF4, platelet 5-HT
DB, PC vs non-DEP
Hergovich et al, 2000
35 Randomized, Healthy 16 Paroxetine (2 weeks) ↓ platelet 5-HT by 83% (CI95: 74-92), 
DB, PC, CS/PO. ↓ collagen/epinephrine induced platelet 
aggregation by 31% (CI95: 6-56), ↓ CD63 by 8% 
(CI95: 4-12)
Alvarez et al, 1999
9 POC DEP vs  27/NA Fluoxetine or  Fluoxetine: ↓ 5-HT plasma to 19% and 
healthy clomipramine platelet to 23%, ↓ of PIT (P<0.02);
(12 weeks) ↓ platelet paroxetine receptor (P=0.03)
Clomipramine: ↓ 5-HT plasma to 8% and platelet 
to 40%, ↓ of PIT (P<0.0001); ↓ platelet paroxetine 
receptor (P=0.05)
Markovitz et al, 2000
24 POC DEP vs  17/21 Sertraline (6 weeks) ↓ collagen-induced platelet secretion 
healthy by 19.5% (P<0.05)
Musselman et al, 2000
25 POC DEP vs  15/12 Paroxetine (6 weeks) ↓ PF4 by 54%, platelet binding MAB 
healthy anti-LIBS by 48% (P=0.0007) and GA6 by 17% 
(P=0.02) (ie, ↓ activation)
Gomez-Gil et al, 2004
30 POC DEP vs  15/15 Imipramine (145 days) ↓ 5-HT induced platelet aggregation 
healthy (P=0.038)
Piletz et al, 2000
16 POC DEP vs healthy 19/17 Bupropion (6-8 weeks) No SS changes in P-selectin levels
Menys et al, 1996
26 CS, POC DEP vs  33/13 Fluoxetine or amitriptyline Fluoxetine: ↓ plasma 5-HT (P<0.005), 
non-treated ↓ 5-HT induced aggregation; amitriptyline: 
no SS changes (P<0.05)
Laine-Cessac et al, 1998
27 PO DEP 8 Fluoxetine ↓ epinephrine-induced platelet aggregation (P<0.025)
Alderman et al, 1996
28 PO DEP 8 Fluoxetine or  No SS changes of platelet aggregation, aPTT, 
paroxetine (28 days) PT, INR, platelet count
Tharmopathy et al, 2000
29 POC DEP 7 Venlafaxine vs tricyclic Spontaneous platelet aggregation,  P-Selectin
Lederbogen et al, 2001
31,32 POC Dep 49 Amitriptyline or Amitriptyline:    prothrombin ratio  
paroxetine (5 weeks) (100.9%, P<0.002); non-SS: ↓ platelet 
aggregation
Paroxetine:    prothrombin ratio (99.1%, P<0.002); 
non-SS: ↓ platelet aggregation
Bang et al, 1991
33 Prosp. op. Healthy 10 Fluoxetine (4-6 weeks) No SS changes in platelet aggregation 
and coagulation factors
Berk et al, 1995
34 Prosp. op. Dep 10 Fluoxetine No SS changes in INR, aPTT, TT, bleeding time, 
factors II, V, VII, VIII:C, IX, X, XI, XII, fibrinogen, 
platelet sensitivity to AA, collagen, ADP, epinephrine
Serebruany et al, 2001
39 In vitro IHD vs healthy 6/7 Sertraline ↓ platelet ADP-collagen-thrombin induced 
aggregability, ↓ P-selectin, CD9, PECAM-I, 
glycoprotein IIb/IIIa and Ib
Mohammad et al, 1974
38 In vitro Healthy NA Imipramine or amitriptyline ↓ ADP-induced platelet aggregation
Bondurant et al, 1998
40 In vitro Healthy 5 Fluoxetine No SS changes in PT
↓
↓
↓association between the degree of 5-HT reuptake inhibi-
tion by antidepressants and the risk of hospital admission
for abnormal bleeding as primary diagnosis was found.
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In these studies,antidepressants were classified according
to their degree of 5-HT reuptake inhibition according to
pharmacological studies.
62,63 Blood transfusion require-
ments during surgery was increased for SRI antidepres-
sant users compared with nonusers,which was not the case
for nonserotonergic antidepressant users.
60 Upper gas-
trointestinal bleeding risk was found to be 12.2 times
greater than expected when there was a concomitant use
of SSRIs and NSAIDs.
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In the prospective laboratory studies mentioned, the
results are heterogenous. Indeed, some studies found
changes in given laboratory tests which were normal in
other studies.Some studies failed to show any modifica-
tion in measured hemostasis markers.
28,33,34 Otherwise,
decrease in platelet/plasma 5-HT level and diminution of
5-HT-induced aggregation are the markers which were
more often modified upon antidepressive treatment,in
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Table II. Clinical studies on modifications of hemostasis markers. DB, double-blind; PC, placebo-controlled; POC, prospective open comparative
study; PO, prospective open; CS,cross-sectional; DEP, depression; SS, statistically significant; MAB, monoclonal antibodies; NA, non-avail-
able; IHD, ischemic heart disease; βTG, β-thromboglobulin; PF4, platelet factor 4; ANOVA, analysis of variance; PECAM, platelet endothe-
lial cell adhesion molecule; 5-HT, serotonin; CI, confidence interval; PIT, platelet inositol triphosphate; LIBS, ligand-induced platelet binding
site; aPTT, partial thromboplastin time; INR, international normalized ratio; TT, thrombin time; AA, arachidonic acid; ADP, adenosine diphos-
phate; PT, prothtrombin time
Table III. Case reports of modifications of hemostasis markers. AA, arachidonic acid; ADP, adenosine diphosphate; aPTT, partial thromboplastin time;
INR, international normalized ratio
Treatment Subject Modifications of hemostasis markers Dechallenge Bleeding
Alderman et al, 1992
41 Fluoxetine 49-year-old  man ↓ ADP-epinephrine-ristocetin-AA- +
(4 days) collagen-induced platelet aggregation
De Maistre et al, 2002
42 Fluoxetine 78-year-old  woman ↓ Epinephrine-induced + Intraperitoneal
(1-year) platelet aggregation hematoma
Aranth et Lindberg,  Fluoxetine  40-year-old woman Platelet count = 131 g/L - Ecchymoses
1992
43 60 mg (2 months)
Leung et Shore,  Fluvoxamine  38-year-old man Platelet count = 142 g/L - Epistaxis, 
1996
44 200 mg ecchymoses
Ottervanger et al,  Paroxetine   27-year-old woman ↓ Epinephrine-induced - Ecchymoses
1994
45 20 mg (4 weeks) platelet aggregation
Evans et al, 1991
46 Fluoxetine 33-year-old  man ↓ ADP-ristocetin-induced platelet  + and  Subdural 
20 mg aggregation; bleeding time > 25 min. rechallenge + hematomas
Humphries et al,  Fluoxetine  44-year-old woman Bleeding time >11.5 min. + Petechiae
1990
47 20 mg (2-years)
Calhoun et Calhoun,  Sertraline  16-year-old woman Bleeding time >12.5 min. + Ecchymoses
1996
48 50 mg (10 weeks)
Ceylan et Alpsan- Sertraline  43-year-old woman Bleeding time =11 min.;  + Hemoptysis, 
Omay, 2005
49 50 mg (7 days) PT =20 sec; platelet count =30 g/L macroscopic 
hematuria
Tham et al, 1999
50 Venlafaxine  47-year-old woman aPTT =89 sec; high antihemophilic  + Ecchymoses
75 mg (2.5 months) factor VIII C antibodies, titre =190 BU/mL
Demet et al, 2005
51 Mirtazapine  54-year-old woman PT =22 sec; INR =2.56; aPTT =34 sec + Ecchymoses
30 mg (10 months)
Hardy et Sirois, 1986
52 Trazodone   40-year-old woman TP =14 sec (before trazodone =20 sec);  -
300 mg (5 weeks) aPTT = 36 sec (before trazodone =44 sec)
+ Warfarin
Tielens, 1997
53 Paroxetine   33-year-old woman aPTT =41 sec - Bruises, excessive 
40 mg (2 weeks) menstrual bloodline with the central role of this neurotransmitter in pri-
mary hemostasis.
9,26,30 Thus, prospective studies clearly
indicate that antidepressants modify primary hemostasis.
However, the configuration and the extent of these
changes remains unspecified.
Most case reports of abnormal bleeding associated with
the use of antidepressants that have failed to demon-
strate perturbations in hemostasis concern the use of
antidepressants with high degree of inhibition of 5-HT
reuptake,
45,57,64-76 or,to a lesser extent,antidepressants with
a mild degree of inhibition of 5-HT reuptake.
77-80This was
also the case for abnormal bleeding case reports with
perturbation of hemostasis markers.In accordance with
classification of antidepressants by their degree of 5-HT
reuptake inhibition,the drugs most frequently associated
with abnormal bleeding are the SSRIs fluoxetine,sertra-
line and paroxetine, thus confirming that 5-HT may
directly be involved in the pathophysiology of bleeding
side effects in patients undergoing antidepressant treat-
ment,and may therefore be a more potent platelet acti-
vator in vivo than in vitro. Interestingly, in those case
reports where coagulation markers were measured,
about half of the patients showed no modification of
hemostasis markers.This is coherent with the observa-
tion that hemostasis tests,when performed in the general
population,in cases of uncomplicated bleeding such as
bruising,have a low sensitivity,ie,show normal results.
The platelet aggregation tests are the most sensitive tests
when modifications of hemostasis markers are suspected
during treatment with antidepressants;however,they are
time-consuming or,unfortunately,not performed in rou-
tine laboratory studies.Furthermore,these tests some-
times give negative results because of genetic factors,
leading to the absence of platelet aggregation. This is
explained by inherited differences in platelet aggregation
(PAR)-1 thrombin receptor levels,and may be clinically
relevant for subjects at increased risk of bleeding.
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Several pertinent questions remain about the clinical rel-
evance of hemostasis modifications by antidepressants.
Should antidepressants be contraindicated in patients
receiving anticoagulation treatment, or suffering from
gastric ulcer,from von Willebrand disease,or from hemo-
philia? Should hemostasis tests be performed in all
patients treated with SSRIs and undergoing surgery?
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What is the correct course to take in case of abnormal
bleeding in a patient treated with an antidepressant?
In our opinion,the above questions are highly relevant
to clinical practice, but it remains difficult to provide
straightforward answers for several reasons.In most of
the publications mentioned, the authors propose no
guidelines for SRI- or SSRI-associated bleeding compli-
cations,arguing that complementary investigations are
still requested.Members of hematological societies are
best equipped to establish guidelines on the above issues.
Such guidelines will help clinicians.In the meantime,we
can nevertheless propose the following general com-
ments.In case of abnormal bleeding in a patient treated
with an SSRI,the pharmacological treatment should be
stopped,and replaced if needed by a non-SSRI antide-
pressant.Patients with a medical history of coagulation
disorders,especially suspected or documented thrombo-
cytopenia or platelet disorder, should be monitored in
case of prescription of any SRI. Platelet dysfunction,
coagulation disorders,and von Willebrand disease (char-
acterized by prolongation of bleeding time combined
with decreased factor VIII procoagulant activity) should
be sought in case of abnormal bleeding occurring during
treatment with any SRI.Platelet aggregation measure-
ment by PFA is the most sensitive laboratory test in these
situations,and should be considered if hemostasis tests
are requested, for example before surgery. Non-SSRI
antidepressants should be preferred to SSRIs or SRIs in
cases of von Willebrand disease,hemophilia,gastric ulcer,
and anticoagulation treatment. ❏
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Influencia de los antidepresivos en la
hemostasis
Los antidepresivos, especialmente los inhibidores
selectivos de la recaptación de serotonina (ISRS), se
utilizan frecuentemente en el tratamiento de la
depresión y los trastornos de ansiedad. La conside-
ración de la depresión como factor de riesgo inde-
pendente que incide en una mayor mortalidad y
morbilidad cardiovascular de pacientes con enfer-
medad cardiaca ischemica, así como la constatación
del papel central de la serotonina en los mecanis-
mos fisiopatológicos de la depresión, y el conoci-
miento de casos de hemorragias anormales produ-
cidas durante tratamientos con antidepresivos, han
llevado a examinar el efecto de los antidepresivos
sobre los medidores de hemostasis. Los fármacos
con mayor grado de inhibición de la recaptación de
serotonina –fluoxetina, paroxetina y sertralina– son
los más frecuentemente asociados con hemorragias
anormales y perturbaciones hemostáticas. Los tras-
tornos hemostáticos más frecuentemente observa-
dos son la disminución de la aglutinación y de la
actividad de las plaquetas, y la prolongación del
tiempo de hemorragia. Generalmente, pacientes
con antecedentes de trastornos de coagulación, en
particular trombocitopenia o disturbio de las pla-
quetas ya diagnosticadas o sospechadas, deberían
estar controlados si se les receta cualquier inhibidor
de la recaptación de serotonina. En caso de hemo-
rragias anormales durante un tratamiento con un
inhibidor de la recaptación de serotonina (IRS), se
debería proceder a la búsqueda de una disfunción
de las plaquetas, una coagulopatia y la enfermedad
de von Willebrand. Teniendo en cuenta la viabili-
dad de realizar las pruebas de aglutinación de las
plaquetas, que son las más sensibles para casos de
hemorragias asociadas con los IRS, y la baja sensi-
bilidad de las pruebas de hemostasis hechas en caso
de hemorragia no complicada en la población
general, el desarrollo de criterios de guía para casos
de hemorragia asociada con los IRS constituye toda-
vía un importante desafío.
Influence des antidépresseurs sur 
l'hémostase
Les antidépresseurs, particulièrement les inhibiteurs
sélectifs de la recapture de la sérotonine (ISRS), sont
largement utilisés dans le traitement des troubles
dépressifs et anxieux. La mise en évidence du fait
que la dépression est un facteur de risque indépen-
dant pour une mortalité et une morbidité cardio-
vasculaire accrue chez les patients souffrant de mala-
die cardiaque ischémique, celle du rôle central de la
sérotonine (5-HT) dans les mécanismes physiopatho-
logiques de la dépression, ainsi que la description de
cas de saignements anormaux sous traitement anti-
dépresseur, ont conduit à examiner l’influence des
antidépresseurs sur les marqueurs de l’hémostase.
Dans cet article, nous avons résumé les données
concernant les variations de ces marqueurs à partir
de cas et d’études cliniques. Nous avons observé une
association entre le type d’antidépresseurs et le
nombre de saignements anormaux avec ou sans
modification des marqueurs de l’hémostase. Les
molécules à haut degré d’inhibition de la recapture
de la sérotonine, la fluoxétine, la paroxétine et la ser-
traline, sont le plus souvent associées à des saigne-
ments anormaux et des modifications des marqueurs
de l’hémostase. Les anomalies hémostatiques le plus
souvent observées sont une diminution de l’agréga-
bilité et de l’activité plaquettaires, ainsi qu’une pro-
longation du temps de saignement. De manière
générale, les patients avec des antécédents de
troubles de la coagulation, en particulier de throm-
bocytopénie ou de trouble plaquettaire connu ou
suspecté, devraient faire l’objet d’une surveillance
accrue en cas de prescription de n’importe quel inhi-
biteur de la recapture de la sérotonine (IRS). Une dys-
fonction plaquettaire, une coagulopathie et une
maladie de Willebrand devraient être recherchées en
cas de saignements anormaux au cours d’un traite-
ment avec un IRS auquel on préférera un antidé-
presseur non IRS dans un tel contexte. Compte tenu
de la difficulté de réalisation des tests d’agrégation
plaquettaire, qui sont les tests les plus sensibles lors
de saignements associés aux IRS, et de la faible sen-
sibilité des tests de l’hémostase réalisés lors de sai-
gnements non compliqués dans la population géné-
rale, la mise en place de recommandations lors de
saignements associés aux IRS reste un défi à relever.Pharmacological aspects
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